Exact Mass: 319.0524
Exact Mass Matches: 319.0524
Found 224 metabolites which its exact mass value is equals to given mass value 319.0524
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Tetrodotoxin
A quinazoline alkaloid that is a marine toxin isolated from fish such as puffer fish. It has been shown to exhibit potential neutotoxicity due to its ability to block voltage-gated sodium channels. D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker Tetrodotoxin. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=4368-28-9 (retrieved 2024-09-06) (CAS RN: 4368-28-9). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
ci no 52015
V - Various > V03 - All other therapeutic products > V03A - All other therapeutic products > V03AB - Antidotes V - Various > V04 - Diagnostic agents > V04C - Other diagnostic agents > V04CG - Tests for gastric secretion COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D004791 - Enzyme Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Ibandronate
Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures. M - Musculo-skeletal system > M05 - Drugs for treatment of bone diseases > M05B - Drugs affecting bone structure and mineralization > M05BA - Bisphosphonates C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates
N-Gluconyl ethanolamine phosphate
N-Gluconyl ethanolamine phosphate is used as a food additive [EAFUS] ("EAFUS: Everything Added to Food in the United States. [http://www.eafus.com/]")
ONO-2235; ONO 2235; ONO2235; Sorbistat
5,9:7,10a-Dimethano-10aH-[1,3]dioxocino[6,5-d]pyrimidine-4,7,10,11,12-pentol, octahydro-12-(hydroxymethyl)-2-imino-,(4R,4aR,5R,7S,9S,10S,10aR,11S,12S)-
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins D049990 - Membrane Transport Modulators
2-Chloro-N-[(Z)-[3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-yl]methylideneamino]benzamide
Sarmazenil
2-(tert-Butylsulfonyl)-3-(3-methylbenzo[b]thiophen-2-yl)acrylonitrile
2-(1,3-benzoxazol-2-ylsulfanyl)-N-(1,3-thiazol-2-yl)butanamide
Hernandonine
An oxoaporphine alkaloid isolated from Hernandia ovigera and Lindera chunii and has been shown exhibit inhibitory activity against HIV-1 integrase .
2-(3,4-dihydro-2-methoxy-4-oxoquinazolinyl)-1H-indole-3-carboxaldehyde|orirenierine B
Cassameridine
An oxoaporphine alkaloid that is 7H-dibenzo[de,g]quinolin-7-one which is substituted by methylenedioxy grups at the 1,2 and 9,10 positions. Compared with liriodenine, which lacks the 9,10-methylenedioxy group, cassameridine displays only moderate antifungal activity.
Epalrestat
C471 - Enzyme Inhibitor > C72880 - Aldose Reductase Inhibitor D004791 - Enzyme Inhibitors
Ibandronate
M - Musculo-skeletal system > M05 - Drugs for treatment of bone diseases > M05B - Drugs affecting bone structure and mineralization > M05BA - Bisphosphonates C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates
N-Gluconyl ethanolamine phosphate
3-[[2-(4-chloro-3-methylphenoxy)acetyl]amino]benzoic acid
Cetophenicol
C254 - Anti-Infective Agent > C52588 - Antibacterial Agent
3-bromo-4-[(4-methylphenyl)methylamino]benzoic acid
Methyl 5,5,5-trifluoro-4-(2-(4-nitrophenyl) hydrazono)pentanoate
3-[4-(METHOXYCARBONYL)PHENYL]-3-[(2,2,2-TRIFLUOROACETYL)AMINO]PROPANOIC ACID
(r)-phenyl-(toluene-4-sulfonylamino)-acetic acid methyl ester
1-(3-Bromo-5-methylpyridin-2-yl)-4-ethylpiperazine hydrochloride
methyl 3-[(2,4-dimethylphenyl)sulfonylamino]benzoate
METHYL 2-(4-METHYLPHENYLSULFONAMIDO)-2-PHENYLACETATE
2-methyl-3-sulfobutyl-5-chlorobenzothiazolium, inner salt
(R)-2-(4-Methylphenylsulfonamido)-3-phenylpropanoicacid
METHYL 4-(ETHYLCARBAMOYL)-2,3-DIFLUORO-[1,1-BIPHENYL]-3-CARBOXYLATE
6,7-Difluoro-1-(4-fluorophenyl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid
2-amino-2-(3,4-dichlorophenyl)-3-[(2-methylpropan-2-yl)oxy]-3-oxopropanoic acid
METHYL2-(PIPERIDIN-4-YLSULFONYL)BENZOATEHYDROCHLORIDE
Bupropion hydrobromide
C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent
4-(4-chloro-2-fluoroanilino)-6-methoxy-1H-quinazolin-7-one
1-Azulenesulfonic acid, 3,8-dimethyl-5-(1-methylethyl)-, sodium salt, hydrate (2:2:1)
3-amino-6-phenyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carbonitrile
2-[2-(4-morpholin-4-ylanilino)-1,3-thiazol-4-yl]acetic acid
N-(2,3-Dihydro-2-oxo-1H-benzimidazol-5-yl)-3-hydroxy-2-naphthalenecarboxamide
4-(6-METHOXY-2-NAPHTHYL)-6-(TRIFLUOROMETHYL)PYRIMIDIN-2-AMINE
5-BROMO-3-(2-PYRIDIN-2-YL-PYRROLIDIN-1-YL)-PYRAZIN-2-YLAMINE
5-BROMO-3-(2-PYRIDIN-3-YL-PYRROLIDIN-1-YL)-PYRAZIN-2-YLAMINE
Ro 19-4603
(1R,2S)-2-(3,4-DIFLUOROPHENYL)CYCLOPROPANAMINE (2R,3R)-2,3-DIHYDROXYSUCCINATE
3-FLUORO-5-(5-((2-METHYLTHIAZOL-4-YL)ETHYNYL)PYRIDIN-2-YL)BENZONITRILE
7-(1,3-Benzothiazol-2-yl)-6-hydroxy-4-oxo-1,4-dihydro-3-quinoline carbonitrile
5-[3,5-Bis(trifluoromethyl)phenyl]-3-pyridinecarbaldehyde
N-[5-Acetyl-2-(benzyloxy)phenyl]methanesulfonamide
N-(4-Chlorobenzoyloxy)-4-nitrobenzimidamide
(R)-ethyl 2-(1-(benzyloxycarbonyl)ethyl)thiazole-5-carboxylate
4-Chloro-6-(trifluoromethoxy)quinoline-3-carboxylic acid ethyl ester
1-(3-Bromophenyl)-2-[(2-methyl-2-propanyl)amino]-1-propanone hydr ochloride (1:1)
METHYL 2-([(4-CHLOROPHENYL)SULFONYL]AMINO)-4-METHYLPENTANOATE
[(1R)-1-(benzyloxycarbonylamino)-2-phenyl-ethyl]phosphinic acid
ETHYL 5-HYDROXY-2-(METHYLTHIO)-7-OXO-8-(PROP-2-YNYL)-7,8-DIHYDROPYRIDO[2,3-D]PYRIMIDINE-6-CARBOXYLATE
1-[6-chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dimethylmethanamine
4-(6-Bromo-4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-pyrimidinamine
Thiazolidine, 2-(4-methylphenyl)-3-(phenylsulfonyl)- (9CI)
n-(2-(4-bromophenoxy)ethyl)piperidine hydrochloride
4-(3-Chloro-2-fluoroanilino)-6-hydroxy-7- methoxyquinazoline
4-(chloromethyl)-2-(4-ethoxy-3-methoxyphenyl)-1,3-thiazole hydrochloride
2-Propanesulfinamide, N-[1-(5-bromo-2-fluorophenyl)ethylidene]-2-methyl-, [N(E),S(S)]-
1-Oxa-8-azaspiro[4,5]decane-8-carboxylic acid,3-bromo-,1,1-dimethylethylester
FAAH-IN-2
FAAH-IN-2 (O-Desmorpholinopropyl Gefitinib) is a potent FAAH(fatty acid amide hydrolase) inhibitor extracted from Patent WO/2008/100977A2.
tert-Butyl 5-chloro-6-(trifluoromethyl)-1H-indole-1-carboxylate
6-Chloro-2-(4-chlorophenyl)imidazo[1,2-α]pyridine-3-acetamide
2-[benzyl-(4-methylphenyl)sulfonyl-amino]acetic acid
(1R)-1-(2-Thienylacetylamino)-1-(3-carboxyphenyl)methylboronic acid
2-([(4-Methylphenyl)sulfonyl]amino)-3-phenylpropanoic acid
2-[(5Z)-5-[(Z)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid
6,11-Dioxo-12-naphtho[2,3-b]indolizinecarboxylic acid ethyl ester
2-Hydroxy-4-methylbenzoic acid [2-(2-chloroanilino)-2-oxoethyl] ester
4-fluoro-N-(4-fluoro-1,3-benzothiazol-2-yl)-1,3-benzothiazol-2-amine
N-(4-methyl-2-thiazolyl)-3-(2-oxo-1,3-benzothiazol-3-yl)propanamide
Benzene, 1,2,3,4,5-pentafluoro-6-((4-nitrophenoxy)methyl)-
(11R,13S)-3-amino-5,12,13,14-tetrahydroxy-14-(hydroxymethyl)-8,10-dioxa-2-aza-4-azoniatetracyclo[7.3.1.17,11.01,6]tetradec-3-en-9-olate
ibandronic acid
M - Musculo-skeletal system > M05 - Drugs for treatment of bone diseases > M05B - Drugs affecting bone structure and mineralization > M05BA - Bisphosphonates C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates